Skip to main content

Table 1 Overview of the schizophrenia patient population

From: The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia

  LAI New User LAI Continuous User LAI Total Oral APT Other Injectable/Unknown Study Total
  n = 235 n = 385 n = 620 n = 377 n = 68 N = 1065
Schizophrenia
 Baseline 214 385 599 281 64 944
 Month 6 173 (80.8) 326 (84.7) 499 (83.3) 230 (81.9) 40 (62.5) 769 (81.5)
 Month 12 156 (72.9) 290 (75.3) 446 (74.5) 204 (72.6) 32 (50.0) 682 (72.2)
  1. APT antipsychotic therapy, LAI long-acting injectable, NA not applicable
  2. Among the 599 patients with schizophrenia in the total LAI group, 482 were receiving PP LAI (174 new users; 308 continuous users) and 117 were receiving RLAI (40 new users; 77 continuous users)
  3. Values in parentheses are percentages unless otherwise specified
  4. New user was defined as a study patient who initiated PP LAI or RLAI treatment within 8 weeks (≤56 days) of the enrollment period
  5. Continuous user was defined as a study patient who initiated PP LAI or RLAI treatment more than 8 weeks (>56 days) after the enrollment visit